<DOC>
	<DOCNO>NCT03068130</DOCNO>
	<brief_summary>This extend access study ass long-term safety tolerability bardoxolone methyl qualify patient pulmonary hypertension ( PH ) previously participate controlled clinical study bardoxolone methyl .</brief_summary>
	<brief_title>Extended Access Program Assess Long-term Safety Bardoxolone Methyl Patients With Pulmonary Hypertension RANGER</brief_title>
	<detailed_description>This extend access study ass long-term safety tolerability bardoxolone methyl qualify patient pulmonary hypertension ( PH ) previously participate controlled clinical study bardoxolone methyl . Qualified patient receive 10 mg bardoxolone methyl daily drug available commercial channel patient withdrawal , whichever sooner . Dose de-escalation ( 5 mg ) permit study , indicate clinically .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Treatmentcompliant patient participate qualify ongoing study complete required EndofTreatment and/or Followup visit prior clinical study bardoxolone methyl Participation investigational clinical study involve interventional product test used way different approve form use unapproved indication ; Patients ongoing SAE clinical study assess investigator related bardoxolone methyl ; Unwilling practice acceptable method birth control ( male partner childbearing potential female childbearing potential ) take study drug ; Women pregnant breastfeeding ; Patient , opinion investigator , unable comply requirement study protocol unsuitable study reason ; Known hypersensitivity component study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>PAH</keyword>
	<keyword>Bardoxolone methyl</keyword>
	<keyword>6-minute walk distance</keyword>
	<keyword>CDDO-ME</keyword>
	<keyword>RTA 402</keyword>
	<keyword>LARIAT</keyword>
	<keyword>CATALYST</keyword>
	<keyword>RANGER</keyword>
</DOC>